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Stereoselective synthesis of c-hydroxynorvaline
through combination of organo- and biocatalysis†
Robert C. Simon,*a Eduardo Busto,a Joerg H. Schrittwieser,a Johann H. Sattler,b
Jo¨rg Pietruszka,c Kurt Fabera and Wolfgang Kroutil*a
An efficient route for the synthesis of all four diastereomers of PMP-
protected a-amino-c-butyrolacton to access c-hydroxynorvaline
was established. The asymmetric key steps comprise an organo-
catalytic Mannich reaction and an enzymatic ketone reduction.
Three reaction steps could be integrated in a one-pot process,
using 2-PrOH both as solvent and as reducing agent. The sequential
construction of stereogenic centres gave access to each of the four
stereoisomers in high yield and with excellent stereocontrol.
Progressive legislative regulations with respect to sustainability, safety
and quality improvements have changed the focus of contemporary
chemical research to designing more economic processes. In this
context, (asymmetric) catalysis has become the method of choice to
replace stoichiometric amounts of reagents and auxiliaries, thereby
facilitating an efficient and energy saving process.1 While each of the
catalysis sub-fields (metal-, organo- and biocatalysis) has reached an
impressive level of sophistication, efficiency can be further increased
by combining methods from these different sub-fields. This allows
exploiting and combining specific features of each type of catalyst in a
highly cooperative fashion. For example, numerous reports have been
published based on the combination of transition metals and
organocatalysts;2 furthermore, biocatalytic transformations have been
coupled with diverse metals.3 However, the combination of bio- and
organocatalysts is still scarce.4,5
a-Amino-g-butyrolactones are common structural elements
in a series of natural products and pharmaceutical drugs that
display diverse biological activities (cf. Fig. 1).6 Moreover, the
corresponding amino acid (g-hydroxynorvaline) has been isolated
from natural sources7 and shows anti-diabetic properties.8 The wide-
spread occurrence of the g-butyrolactone unit has led to the develop-
ment of a number of stereoselective syntheses mainly based on
chemo-catalysis,9 while only few biocatalytic strategies have been
developed.10 Most of the procedures either require multiple steps,
are auxiliary-assisted, or based on ex-chiral pool precursors.11 Hence,
access to only one or two out of four stereoisomers is provided.
However, as the biological activity of bioactive compounds is related
often to one specific unknown stereoisomer,12 a convenient access to
all four diastereomers, e.g. for SAR-studies, is desired.
In this communication, a novel combination of organo- and
biocatalysis is reported, which provides access to optically pure
a-amino-g-butyrolactones either in a step-wise fashion or in a
cascade reaction.
In our study we focused initially on the bioreduction of
racemic amino-ketoester rac-1, which is readily available by a
proline catalysed Mannich reaction.13,14 A set of homo- and
heterologously expressed alcohol dehydrogenases (ADHs)15 were
assayed on analytical scale (5.6 mg, 20 mM) employing 2-propanol
for NAD(P)+ regeneration. Asymmetric reduction of the carbonyl
group of amino-ketoester 1 afforded the corresponding diastereo-
mers of alcohol 2, which cyclised spontaneously to the desired
2-amino-lactones 3 (Scheme 1).
A number of ADHs transformed rac-1 into the corresponding
a-amino-lactones 3 with high conversion (selected results in
Table 1; more details in the ESI†). For example, the (5S)-configured
diastereomers (3S,5S)-3 and (3R,5S)-3 were accessible by the
enzymes ADH-A15a (entry 1) and evo-1.1.03015b (entry 2), whereas
the (5R)-diastereomers (3S,5R)-3 and (3R,5R)-3were formed utilising
evo-1.1.20015b (entry 5). The enzymes ADH-T15c (entry 3) and
ADH-LS15d (entry 4) gave excellent results, too, with conversions
Fig. 1 Selected bioactive compounds containing a-amino-g-butyro-lactones.
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of 83% and 86%, respectively. In all cases, the enantiomeric
excess (ee) of all diastereomers of lactones 3 was 499%.
Among the enzymes tested, ADH-LB15e and evo-1.1.27015b gave
unexpected results as in both casesmainly one diastereomer (3S,5R)-3
was detected (entries 6 and 7). Since the conversions remained below
50%, we assumed a selective kinetic resolution with respect to the
existing stereogenic centre in b-position to the carbonyl group. In
order to gain a better understanding of such a rare case of distant
stereorecognition by ADHs,16 further investigations were performed:
racemic and enantiopureMannich-bases rac-/(R)-/(S)-1were incubated
with ADH-LB and the reaction progress was monitored over
time (Fig. 2). Thereby it was found that rac-1 gave the (3S,5R)-3
diastereomer as sole product with 40% conversion after eight hours,
while (R)-1 was not transformed. The pure enantiomer (S)-1 reacted
fastest, reaching 70% conversion within the same time.
The experimental observations were additionally supported
by in silico docking studies: only substrate (S)-1 was found to fit in
the active site enabling a productive binding mode; the substrate
occupies therein a pro-R conformation in which the carbonyl
group can be activated by two hydrogen bonds through amino
acids Tyr152 and Ser142 (Fig. 3). Attempts to dock the opposite
enantiomer (R)-1 into the active site failed to provide a reasonable
productive binding mode (see ESI†). Hence, the structure of
ADH-LB allows a chiral recognition of a remote stereocentre
enabling a kinetic resolution.16 Attempts to couple the diaster-
eoselective reduction of 1 with a racemisation of 1 in a dynamic
kinetic resolution failed so far due spontaneous degradation of
1 via elimination of anisidine over time.
The next step was the synthesis of all four stereoisomers of
amino-lactone 3; for this purpose, the biocatalysed reduction
of ketoester 1 was optimised using alcohol dehydrogenases
ADH-A and evo-1.1.200. Investigating 2-PrOH as a cosolvent revealed
that a substrate concentration of 30 mM (7.95 mg mL1, 10 vol%
2-PrOH) led to completion of the reaction in the case of the
(S)-selective ADH-A within 24 h (for details, see ESI†). The (R)-selective
enzyme evo-1.1.200 transformed even 50 mM (13.3 mg mL1, 30 vol%
2-PrOH) to completion within 24 h. The optimum pH was determined
to be 6.3 in order to keep the partial racemisation of the optically pure
Mannich adduct 1 at a minimum (see ESI†). In the subsequent
semi-preparative scale transformations [56 mg (S)-1]499% conver-
sion was achieved; however, ring closure was incomplete, as mainly
the optically pure amino-alcohol 2 rather than the lactone 3 was
isolated (ca. 50–70%; see ESI†).17 Assuming that the corresponding
methyl ester of 1 would undergo faster lactonisation than the ethyl
analogue, a transesterification step (HCl–MeOH) was integrated into
the reaction sequence. The optimised conditions finally allowed
conversion of the pure amino-ester (R)-/(S)-1 (up to 4300 mg),
readily accessible by a proline-catalysed Mannich reaction of
acetone and imine 4,14 into the corresponding lactones 3. The
syn- and anti-diastereomers were isolated in excellent yields
(78–82%) and with remarkable stereocontrol (de498 : 2 and ee
499% in all cases; see Scheme 2).
As an alternative to the conventional step-by-step synthesis
(Scheme 2) two sequential approaches were established. In a
first approach, aldimine 4 was formed in 2-PrOH, which also
served as a solvent for the subsequent Mannich reaction and as
Scheme 1 Alcohol dehydrogenase catalysed reduction of racemic ketoester
rac-1 on analytical scale (20 mM, 5.6 mg). PMP = para-methoxyphenyl.
Table 1 Selected results of the ADH catalysed reduction of ketoester
rac-1 yielding lactone 3 (analytical scale, double determination)a
Entry Enzyme Conv.b [%] d.r. [syn/anti]b eesyn 3
c [%] eeanti 3
c [%]
1 ADH-A 99 52/48 499 (3R,5S) 499 (3S,5S)
2 evo-1.1.030 99 51/49 499 (3R,5S) 499 (3S,5S)
3 ADH-T 83 12/88 499 (3R,5S) 499 (3S,5S)
4 ADH-LS 86 71/29 499 (3S,5R) 499 (3R,5R)
5 evo-1.1.200 99 52/48 499 (3S,5R) 499 (3R,5R)
6 ADH-LB 49 99/1 499 (3S,5R) —
7 evo-1.1.270 49 99/1 499 (3S,5R) —
a Reaction conditions: ketoester rac-1 (5.6 mg, 20mM), KPi buffer (100mM,
pH 6.8), NAD(P)+ (1.0 mM), 10 vol% 2-PrOH, ADH (for units see ESI), 30 1C,
700 rpm on a thermoshaker (horizontal position), 24 h. b Determined
via GC on an achiral stationary phase. c Determined via HPLC on a
chiral stationary phase.
Fig. 2 Time course of the biocatalytic reduction of racemic and enantio-
pure Mannich-base 1 with the enzyme ADH-LB (double determination).
Fig. 3 Docking study: productive binding mode of Mannich-base (S)-1
(purple) and the cofactor NADP+ (orange) in the active site of ADH-LB.
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the reducing agent for the enzyme-mediated reduction (after dilution
with buffer solution). All three steps were accomplished in one pot,
after which the transesterification-lactonisation cascade was
performed in a separate vessel. The whole sequence afforded
the syn-configured lactone (3S,5R)-3 in a remarkable 47% yield
with a d.r. of 86/14 in favour of the syn-diastereomer (Scheme 3a:
5 steps in total, 2 pots, 90% average yield per step). The dimin-
ished d.r. in comparison to the previous results can be rationa-
lised by the usage of 2-PrOH for the proline-catalysed reaction,
which under these conditions afforded (S)-1 with 72% ee.
In a second approach, the Mannich reaction was carried out
with the preformed aldimine 4 in acetone as solvent, and amino-
ketoester (R)-1 was obtained at prolonged reaction time (16 h) with
499% conversion and in optically pure form (ee 499%). After
evaporation of the solvent, the crude product was subjected to
reduction by ADH-A in buffer–2-PrOH. The final transesterification-
lactonisation cascade furnished the diastereomerically pure amino
lactone (3R,5S)-3 in 51% yield with an excellent d.r. of 99 : 1
(Scheme 3b: 4 steps, 2 pots, 85% average yield per step).
Final PMP-deprotection of the diastereomerically pure a-amino-
lactone 3was achieved employing TCCA (trichloroisocyanuric acid) in
MeOH,18b providing the hydrochloride salt of 6. Unexpectedly, other
oxidative deprotectionmethods [PhI(OAc)2, CAN, HIO6, laccase, etc.]
18
were unsuccessful. Intensive optimisation of the purification of 6with
respect to the solvent, acid, reaction time and work-up procedure
finally provided access to g-hydroxynorvaline: the natural pro-
duct was isolated diastereomerically pure after a base promoted
ring opening (58% yield over two steps) as demonstrated for the
(2R,4S)-diastereomer (Scheme 4).
In conclusion, a straightforward synthesis of all four diastereo-
mers of PMP-protected a-amino-g-butyrolactone to access g-hydroxy-
norvaline has been established. The sequential construction of the
stereogenic centres was accomplished by combination of organo-
and biocatalysed key steps. In one approach, three sequential steps
including the organo- as well as the biocatalysed transforma-
tions were performed in one pot, integrating 2-propanol first as
solvent and then as reducing agent.
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by the Austrian BMWFJ, BMVIT, SFG, Standortagentur Tirol and
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